Beijing Jingdu Children's Hospital

What Beijing Jingdu Children's Hospital does

Beijing Jingdu Children's Hospital is a private, for-profit pediatric tertiary hospital founded in 2015 in Beijing's Changping District by Dr. Sun Yuan, operating from a 40,000 square meter modern facility with 19 independent laminar-flow HSCT wards, dedicated PICU and NICU beds, and JCI accreditation. The hospital functions as Asia's largest pediatric hematopoietic stem cell transplantation (HSCT) center, having completed approximately 900 HSCT procedures (45% relapsed/refractory cases) with a reported 78% success rate, alongside over 2,000 pediatric congenital heart disease surgeries, and runs Asia's leading pediatric CAR-T program with an 83% objective response rate in relapsed/refractory leukemia. Its clinical stack is built around proprietary protocols including the "Jingdu Protocol" for ETP-ALL and 12 distinctive relapsed/refractory leukemia regimens validated across 860 cases, supported by advanced MRD monitoring at 10^-6 sensitivity, NGS sequencing, haploidentical and cord blood transplantation, and triple-combination HSCT techniques.

The hospital's commercial model combines routine pediatric outpatient/inpatient services (620,000+ annual outpatient visits, 10,000+ inpatient admissions) with high-acuity specialty care priced at premium levels for international patients. Revenue is generated across three streams: standard patient medical services, dedicated International Patient Services (multilingual support in English, Japanese, Russian, Korean; visa assistance; insurance billing; medical concierge), and VIP wards. Demand is sourced from over 100 countries through international referrals, second opinion requests, patient testimonials, and academic case-discussion partnerships with St. Jude Children's Research Hospital (USA) and Children's Hospital of the University of Munich (Germany), as well as from domestic Beijing-area families. Distribution runs through online booking (website and WeChat mini-program), 24-hour phone reservations, walk-in registration, and a dedicated International Department. In February 2026 the hospital extended into preventive care by launching a Vaccination Clinic for Foreign Children offering internationally compatible bilingual immunization records, opening a new recurring-revenue segment targeted at expatriate families.

Name

Beijing Jingdu Children's Hospital

Legal name

Beijing Jingdu Children's Hospital

Website

https://jdetyy.com

Company type

Private

Founded year

2015

Operating status

Operating

Headcount range

101–250 employees

Short description

Beijing Jingdu Children's Hospital is a private JCI-accredited pediatric tertiary hospital in Beijing and Asia's largest pediatric HSCT center, treating complex hematology, oncology, and cardiac cases for domestic and international patients from 100+ countries.

Ownership category

akta.pro rank

Product category

Pediatric Specialty Healthcare Services

NAICS

Specialty (except Psychiatric and Substance Abuse) Hospitals (622310)

SIC

Services-Hospitals (8060)

akta.pro industry

PRIMARYHLAFAJAG

Children’s Hospitals & Pediatric Health Systems

Healthcare & Life Sciences/Healthcare Providers & Systems/Women’s & Children’s Health Providers

SECONDARYHLAFAJAH

Pediatric Specialty Care Centers (e.g., cardiology, oncology, neurology)

Healthcare & Life Sciences/Healthcare Providers & Systems/Women’s & Children’s Health Providers

SECONDARYHLAKAFAE

Pediatric Hematology & Oncology

Healthcare & Life Sciences/Specialist Medical Practice/Hematology & Oncology

Keywords

• Pediatric hematology services
• Hematopoietic stem cell transplantation
• Pediatric oncology treatment
• International patient services
• Children's specialty hospital

Headquarters

HQ city

Beijing

HQ country

China

HQ region

Asia

Offices1 record

Markets served

GTM type

B2C

Offering type

Services

Cost components

Personnel, Operations, Infrastructure, Technology or R&D, Marketing or Sales

Revenue model

1. Patient Medical Services Revenue: Revenue generated from comprehensive pediatric medical services including consultations, diagnostic tests, treatments, surgical procedures, stem cell transplantation, and inpatient/outpatient care across all specialties.
2. International Patient Services: Revenue from international patients covering visa assistance, multilingual support, medical concierge, cost estimation, insurance and billing services, and international medical transport services.
3. VIP Services: Premium patient services including VIP wards, specialized nursing, and personalized treatment plans generating additional revenue above standard care.

Pricing tiers

Go-to-market motion1 record

Distribution channels5 records

Marketing channels5 records

Core offering

Beijing Jingdu Children's Hospital is a private, JCI-accredited pediatric specialty hospital providing comprehensive medical services including hematology, oncology, hematopoietic stem cell transplantation (HSCT), cardiothoracic surgery, orthopedics, hemangioma interventional therapy, and international patient services. It operates Asia's largest pediatric HSCT center, treating complex, refractory, and high-risk pediatric conditions using advanced therapies such as CAR-T, haploidentical transplantation, and the proprietary Jingdu Protocol.

Product overview

Beijing Jingdu Children's Hospital operates as a comprehensive pediatric hospital with multiple specialized departments working collaboratively. The core services center around Asia's #1 Pediatric Stem Cell Transplant Center specializing in hematopoietic stem cell transplantation (HSCT) for leukemia, thalassemia, and primary immunodeficiencies. Key service lines include the Hematology Department (offering CAR-T therapy, haplo-HSCT, and cord blood transplantation), Pediatric Oncology Center (treating neuroblastoma, hepatoblastoma, rhabdomyosarcoma), Cardiothoracic Surgery (including congenital heart disease), Orthopedics (cerebral palsy treatment), and Hemangioma Interventional Therapy Center. The hospital also provides dedicated International Patient Services with multilingual support and a Vaccination Clinic for Foreign Children. The hospital features a modern 40,000 square meter facility with JCI accreditation.

Differentiator

Problem solved

Functional benefit

Products and services

• Hematology Department (Pediatric HSCT Center)

Quantifiable outcome

• HSCT transplantation success rate: 78%
• +17 more outcomes

Named customers2 records

Segments4 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Partnerships

Three partnerships are on record, tiered core and minor.

• St. Jude Children's Research Hospital (USA)coreStrategic or Co-development PartnerBeijing Jingdu Children's Hospital conducts in-depth case discussions with St. Jude Children's Research Hospital at least 8 times annually, achieving over 95% accuracy in addressing complex leukemia cases. This collaboration enhances treatment protocols for relapsed/refractory leukemia and advances clinical expertise through international knowledge exchange.
• Children's Hospital of the University of Munich (Germany)coreStrategic or Co-development PartnerInternational academic collaboration involving case discussions and knowledge exchange in pediatric hematology and leukemia treatment. The partnership contributes to accuracy rates exceeding 95% in complex case management.
• International CAEBV Consortium / iCAEBV RegistryminorStrategic or Co-development PartnerInternational registry integrating data from 1,865 patients across 41 countries for chronic active Epstein-Barr virus disease. Machine learning models predict disease progression risk (AUC=0.93). Beijing Jingdu Children's Hospital contributes clinical data and participates in international research efforts.

Scale indicators14 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Beijing Children's Hospital (Capital Medical University): National pediatric tertiary center and former employer of Prof. Wu Minyuan, who led its Hematology Center. Direct competitor for complex pediatric hematology/oncology cases in Beijing and across northern China, with overlapping specialty capability and national referral status.
• Beijing Daopei Hospital: One of China's leading private pediatric hematology and HSCT centers and the prior employer of founder Dr. Sun Yuan. Directly comparable as a competing destination for pediatric HSCT and complex leukemia cases, with overlapping protocols and a similar international patient focus.
• Children's Hospital of Fudan University: One of China's largest public pediatric tertiary centers, with strong hematology, oncology, and HSCT programs. A primary domestic competitor for high-risk pediatric leukemia and transplant cases outside Beijing.

Broad incumbents

• Boston Children's Hospital: Major U.S. pediatric academic medical center with leading HSCT, oncology, and CAR-T programs. Competes for international pediatric hematology referrals and is a global benchmark Jingdu is positioning against.
• St. Jude Children's Research Hospital: Globally recognized pediatric oncology and HSCT research hospital. Jingdu conducts joint case discussions with St. Jude and competes with it for international referrals in relapsed/refractory pediatric leukemia, though St. Jude operates at a much larger scale and treats patients free of charge.
• Children's Hospital of Philadelphia (CHOP): Top-ranked U.S. pediatric hospital with one of the largest pediatric HSCT programs globally. Competes for international relapsed/refractory leukemia and CAR-T referrals and represents the upper bound of outcomes and reputation in the space.

Regional players

• Great Ormond Street Hospital (GOSH): Leading UK pediatric hospital and a major destination for complex pediatric HSCT and rare disease referrals from the Middle East, Africa, and Asia. Competes with Jingdu for international cases from those regions.
• King Faisal Specialist Hospital & Research Centre: Saudi Arabia's leading tertiary and referral hospital with significant pediatric HSCT and oncology capacity. Competes with Jingdu for Middle Eastern pediatric hematology patients and is a high-prestige regional alternative.
• Apollo Hospitals – Children's: India's largest private hospital network with established pediatric hematology, oncology, and HSCT programs. Competes with Jingdu for South Asian and Middle Eastern pediatric transplant referrals, typically at lower price points.
• National University Hospital – Khoo Teck Puat – National University Children's Medical Institute: Singapore's leading pediatric tertiary center with strong HSCT and oncology programs. Competes with Jingdu for Southeast Asian and ASEAN complex pediatric cases, particularly leukemia and thalassemia.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat6 records

Key risks5 records

Key highlights7 records

Customer concentration

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles7 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Beijing Jingdu Children's Hospital